Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Neoplasm: early-phase trial registry
2 of 4 indexed Head and Neck Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Head and Neck Neoplasm: 4 US clinical trials tracked, 2 recruiting.
Head and Neck Neoplasm is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is UNC Lineberger Comprehensive Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition head-and-neck-neoplasm
OPEN 2 | RECR 50% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Head and Neck Neoplasm lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Neoplasm is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Oropharynx (OPX) Biomarker Trial
Mayo Clinic
NCT06356272
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT04099290
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
National Cancer Institute (NCI)
NCT00001442
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Medical College of Wisconsin
NCT04477759
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Neoplasm page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Head and Neck Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UNC Lineberger Comprehensive Cancer Center sponsors the most Head and Neck Neoplasm trials on record, review their full trial history before evaluating a specific study. See UNC Lineberger Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Neoplasm condition card totals 4 registered trials; most-linked intervention Adjuvant Atezolizumab; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.